Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients

Background. The most important task in the field of renal-cell cancer (RCC) treatment results improvement is the search and validation of the markers for its early diagnostics still absent in the clinical practice. It was established that even before the onset and/or detection of RCC the level of kidney injury molecule-1 (KIM-1) in blood plasma did increase.

Objective of the study — comparative evaluation of KIM-1 levels in blood plasma of practically healthy persons, RCC cancer, benign kidney tumor patients, patients with non-oncological renal pathologies, and analysis of its role in RCC diagnostics and prognosis.

Materials and methods. 125 RCC (age 33—81 years), 14 — benign kidney neoplasms (29—84 years) patients, 90patients with chronic nephritis (28—82 years) and 68 practically healthy persons (18—71 years) were included in the study. Plasma KIM-1 content was measured using Human Serum TIM-1/KIM-1/HAVCR Quantikine® ELISA kit (R&D Systems Biotechne®, USA).

Results. KIM-1 level in blood plasma of RCC and chronic nephritis patients was significantly higher than in control (medians 305, 282 and 37.8pg/ml respectively, p <0.0001). The rate of KIM-1 elevation over cut-offvalue 90pg/ml corresponding to the upper 95 % confidence interval of control in RCC patients comprised 79.2 %, in patients with nephritis — 83 %, in those with benign renal tumors — 50 %. Specificity in relation to healthy control was 96 %. KIM-1 level highly significantly increased with RCC progression, and already at stage I was 4.3-fold higher by median than in control (p <0.0001). Sensitivity of stage I—IIRCC detection at cut-off 90pg/ml comprised 75 %; stage III—IV — 94 %. The highest plasma KIM-1 levels were detected in papillary cancer patients (median 644pg/ml), that was more than 2-fold higher than in clear-cell and 32-fold higher than in chromophobic RCC. Plasma KIM-1 median level was 7-fold higher in patients with G3 4RCC than in those with G12 (p <0.0001). At the cut-off KIM-1 value of 163pg/ml, corresponding to the median at stage I, significant differences in 3.5-years overall survival both in the total group: 49 % at high, 95 % at low marker level (p <0.01), and at stage I RCC: 62 % and 100 % respectively (p <0.05) — were revealed.

Conclusion. Plasma KIM-1 may become the first highly sensitive marker for the early detection of RCC, but it does not allow differentiating between oncologic and non-oncologic renal pathologies. Increased basal plasma KIM-1 is an unfavorable prognostic factor irrespective of the stage of tumor progression.

1. Scelo G., Muller D.C., Riboli E. et al. KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin Cancer Res 2018;24(22):5594—601. DOI: 10.1158/1078-0432.CCR-18-1496.

2. Rennert P.D. Novel roles for TIM-1 in immunity and infection. Immunol Lett 2011;141(1):28—35. DOI: 10.1016/j.imlet.2011.08.003.

3. Brooks C.R., Yeung M.Y., Brooks Y.S. et al. KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1- dependent clearance of apoptotic cells to antigen presentation. EMBO J 2015;34(19):2441—64. DOI: 10.15252/embj.201489838.

4. Ichimura T., Bonventre J.V., Bailly V. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273(7):4135—42. DOI: 10.1074/jbc.273.7.4135.

5. Yang L., Brooks C.R., Xiao S. et al. KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest 2015;125(4):1620—36. DOI: 10.1172/JCI75417.

6. Bonventre J.V. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 2009;24(11):3265—68. DOI: 10.1093/ndt/gfp010.

7. Assadi F., Sharbaf F.G. Urine KIM-1 as a potential biomarker of acute renal injury after circulatory collapse in children. Pediatr Emerg Care 2019;35(2):104-7. DOI: 10.1097/PEC.0000000000000886.

8. Schulz C.A., Engstrom G., Nilsson J. et al. Plasma kidney injury molecule-1 (p-KIM-1) levels and deterioration of kidney function over 16 years. Nephrol Dial Transplant 2020;35(2):265-73. DOI: 10.1093/ndt/gfy382.

9. Moresco R.N., Bochi G.V., Stein C.S. et al. Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta 2018;487:15-21. DOI: 10.1016/j.cca.2018.09.011.

10. Bailly V., Zhang Z., Meier W. et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277(42):39739-48. DOI: 10.1074/jbc.M200562200.

11. Bonventre J.V. Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 2008;241:78-83. DOI: 10.1080/00365510802145059.

12. Gershtein E.S., Kushlinskii N.E. Marker KIM-1 in the early diagnosis of renal cell carcinoma. Tekhnologiya zhivykh system = Technologies of Living Systems 2019;16(1):5-20. (In Russ.). DOI: 10.18127/j20700997-201901-01.

13. Solokhina M.P., Sergeeva N.S., Marshutina N.V. et al. KIM-1 as a potential serological/ urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity. Onkourologiya = Cancer Urology 2019;15(3):132-42. (In Russ.). DOI: 10.17650/1726-9776-2019-15-3-132-142.

14. Shalabi A., Abassi Z., Awad H. et al. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma. World J Urol 2013;31(6):1541-45. DOI: 10.1007/s00345-013-1043-1.

15. Han W.K., Bailly V., Abichandani R. et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62(1):237-44. DOI: 10.1046/j.1523-1755.2002.00433.x.

16. Morrissey J.J., London A.N., Lambert M.C., Kharasch E.D. Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol 2011;34(5):391-8. DOI: 10.1159/000330851.

17. Cuadros T., Trilla E., Vila M.R. et al. Hepatitis A virus cellular receptor 1/ kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/ kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. Eur J Cancer 2013;49(8):2034-47. DOI: 10.1016/j.ejca.2012.12.020.

18. Kanukoev K.Yu., Sergeeva N.S., Karmakova T.A. et al. KIM-1 (kidney injury molecule 1) in the urine of renal cell carcinoma patients. Onkourologiya = Cancer Urology 2020;16(3):21-8. (In Russ.). DOI: 10.17650/1726-9776-2020-16-3-21-28.

19. Cuadros T., Trilla E., Sarro E. et al. HAVCR/KIM-1 activates the IL-6/ STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res 2014;74(5):1416-28. DOI: 10.1158/0008-5472.CAN-13-1671.

20. Kushlinskii N.E., Gershtein E.S., Naberezhnov D.S. et al. Kidney Injury Molecule-1 (KIM-1) in blood plasma of patients with clear-cell carcinoma. Bull Exp Biol Med 2019;167(3):388-92. DOI: 10.1007/s10517-019-04533-w.

21. Han W.K., Alinani A., Wu C.L. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005;16(4):1126-34. DOI: 10.1681/ASN.2004070530.

22. Zhang P.L., Mashni J.W., Sabbisetti V.S. et al. Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma. Int Urol Nephrol 2014;46(2):379-88. DOI: 10.1007/s11255-013-0522-z.